BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38670592)

  • 1. Genetic Analyses of Primary Liver Cancer Cell Lines: Correspondence With Morphological Features of Original Tumors.
    Akiba J; Ogasawara S; Yano H
    Cancer Genomics Proteomics; 2024; 21(3):260-271. PubMed ID: 38670592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
    Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
    J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
    Calderaro J; Couchy G; Imbeaud S; Amaddeo G; Letouzé E; Blanc JF; Laurent C; Hajji Y; Azoulay D; Bioulac-Sage P; Nault JC; Zucman-Rossi J
    J Hepatol; 2017 Oct; 67(4):727-738. PubMed ID: 28532995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
    Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
    Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
    Ye S; Zhao XY; Hu XG; Li T; Xu QR; Yang HM; Huang DS; Yang L
    Oncol Rep; 2017 Apr; 37(4):2215-2226. PubMed ID: 28350084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD44 in human hepatocellular carcinoma cell lines.
    Haramaki M; Yano H; Fukuda K; Momosaki S; Ogasawara S; Kojiro M
    Hepatology; 1995 May; 21(5):1276-84. PubMed ID: 7537711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing.
    Jeon J; Maeng LS; Bae YJ; Lee EJ; Yoon YC; Yoon N
    Cancer Genomics Proteomics; 2018; 15(4):291-298. PubMed ID: 29976634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
    Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
    J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological heterogeneity in beta-catenin-mutated hepatocellular carcinomas: implications for tumor molecular classification.
    Torbenson M; McCabe CE; O'Brien DR; Yin J; Bainter T; Tran NH; Yasir S; Chen ZE; Dhanasekaran R; Ahn KS; Roberts LR; Wang C
    Hum Pathol; 2022 Jan; 119():15-27. PubMed ID: 34592239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
    Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
    Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
    J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.
    Li W; Wu H; Xu X; Zhang Y
    Aging (Albany NY); 2021 Apr; 13(8):11564-11594. PubMed ID: 33867349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis.
    Kim SK; Takeda H; Takai A; Matsumoto T; Kakiuchi N; Yokoyama A; Yoshida K; Kaido T; Uemoto S; Minamiguchi S; Haga H; Shiraishi Y; Miyano S; Seno H; Ogawa S; Marusawa H
    J Gastroenterol; 2019 Jul; 54(7):628-640. PubMed ID: 30756187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    Wang Y; Hong Y; Li M; Long J; Zhao YP; Zhang JX; Li Q; You H; Tong WM; Jia JD; Huang J
    PLoS One; 2013; 8(12):e82426. PubMed ID: 24349281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
    Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J
    Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
    Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
    Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
    Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
    J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.
    Nault JC; Martin Y; Caruso S; Hirsch TZ; Bayard Q; Calderaro J; Charpy C; Copie-Bergman C; Ziol M; Bioulac-Sage P; Couchy G; Blanc JF; Nahon P; Amaddeo G; Ganne-Carrie N; Morcrette G; Chiche L; Duvoux C; Faivre S; Laurent A; Imbeaud S; Rebouissou S; Llovet JM; Seror O; Letouzé E; Zucman-Rossi J
    Hepatology; 2020 Jan; 71(1):164-182. PubMed ID: 31206197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
    Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
    Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.